Abbott India Ltd vs Lasa Supergenerics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Abbott India Ltd is ₹ 25430 as of 30 Apr 15:30 . The P/E Ratio of Abbott India Ltd changed from 46.1 on March 2021 to 46.2 on March 2025 . This represents a CAGR of 0.04% over 5 yearsThe P/E Ratio of Lasa Supergenerics Ltd changed from 10.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Abbott India Ltd changed from ₹ 31850 crore on March 2021 to ₹ 65302 crore on March 2025 . This represents a CAGR of 15.44% over 5 yearsThe Market Cap of Lasa Supergenerics Ltd changed from ₹ 243.63 crore on March 2021 to ₹ 84.42 crore on March 2025 . This represents a CAGR of -19.10% over 5 years The revenue of Abbott India Ltd for the Dec '25 is ₹ 1793 crore as compare to the Sep '25 revenue of ₹ 1827 crore. This represent the decline of -1.82% The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 2.22 crore as compare to the Sep '25 revenue of ₹ 3.07 crore. This represent the decline of -27.69% The ebitda of Abbott India Ltd for the Dec '25 is ₹ 533.23 crore as compare to the Sep '25 ebitda of ₹ 572.12 crore. This represent the decline of -6.8% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ -0.73 crore as compare to the Sep '25 ebitda of ₹ -3.99 crore. This represent the decline of -81.7% The net profit of Abbott India Ltd changed from ₹ 328.01 crore to ₹ 375.96 crore over 7 quarters. This represents a CAGR of 8.11% The net profit of Lasa Supergenerics Ltd changed from ₹ -2.73 crore to ₹ -2.55 crore over 7 quarters. This represents a CAGR of -3.82% The Dividend Payout of Abbott India Ltd changed from 84.61 % on March 2021 to 71.36 % on March 2025 . This represents a CAGR of -3.35% over 5 yearsThe Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Abbott India Ltd

Abbott India Limited was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Limited.
The company name was changed to 'The Boots Company (India) Limited' on November 1, 1971, thereafter to Boots Pharmaceuticals Limited on January 1, 1991.
In October, 1995 the name was changed to Knoll Pharmaceuticals Limited, and in July, 2002, they got their present name 'Abbott India Limited'. Company is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country.
The Company sells its products through independent distributors primarily within India.
It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

FAQs for the comparison of Abbott India Ltd and Lasa Supergenerics Ltd

Which company has a larger market capitalization, Abbott India Ltd or Lasa Supergenerics Ltd?

Market cap of Abbott India Ltd is 54,040 Cr while Market cap of Lasa Supergenerics Ltd is 39 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Lasa Supergenerics Ltd?

The stock performance of Abbott India Ltd and Lasa Supergenerics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Lasa Supergenerics Ltd?

As of May 4, 2026, the Abbott India Ltd stock price is INR ₹25430.9. On the other hand, Lasa Supergenerics Ltd stock price is INR ₹7.96.

How do dividend payouts of Abbott India Ltd and Lasa Supergenerics Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Lasa Supergenerics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.